AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 ...

VALENCIA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin

Related Keywords

Germany ,Japan ,Valencia ,Carabobo ,Venezuela ,Austria ,Switzerland ,Australia ,United States ,Australian ,Jim Corbett ,Nasdaq ,Us Department Of Health ,Drug Administration ,Biomedical Advanced Research ,Development Authority ,Human Services ,Drug Administration Food ,Chief Executive ,Biosynthetic Wound Matrix ,Assistant Secretary ,Conference Call ,Eastern Daylight Time ,Spray On Skin ,Private Securities Litigation Reform Act ,Annual Report ,Chief Financial Officer ,Media Contact ,Jessica Ekeberg Phone ,Region ,